Fast fol­low: EQRx en­gi­neers $410M-plus worth of deals to CDK4/6, EGFR drugs

Alex­is Borisy and Melanie Nal­licheri have giv­en the world a first glimpse at the mar­kets they want to dis­rupt, as EQRx un­veils the li­cens­ing of two drugs that it’s now rush­ing to de­vel­op and com­mer­cial­ize — at a promised steep dis­count to ri­vals.

Both le­ro­ci­clib from G1 Ther­a­peu­tics and al­moner­tinib from Han­soh Phar­ma are what EQRx dubs “fast fol­low” med­i­cines, with the same tar­gets as ap­proved can­cer drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER